Korean J Fam Med Search


Korean J Fam Med > Volume 42(2); 2021 > Article
Pornsuriyasak, Rattanasiri, Unwanatham, Kawamatawong, Jankum, and Thakkinstian: Effects of Oral Procaterol for Postinfectious Cough in Adults: Single-Centre, Randomized Double-Blind, Placebo-Controlled Trial



Persistent cough following an upper respiratory tract infection (URTI) is common in clinical practice. We investigated the effects of procaterol on cough-specific quality of life (QoL) and peripheral-airway function among adults suffering from postinfectious cough (PIC).


This was a prospective, randomized, double-blinded placebo-controlled trial (NCT 02349919) conducted at a university hospital. Seventy-four non-asthmatic adults who had persistent post-URTI cough for ≥3 weeks were assessed by a physical examination, chest/paranasal sinus radiographs, spirometry, and impulse oscillometry (IOS) and were allocated to receive procaterol or placebo for 4 weeks. The Thai version of the Leicester Cough Questionnaire (LCQ-T), spirometry and IOS were assessed at baseline, 2 weeks, and 4 weeks.


Mean LCQ-T total scores for the procaterol group (10.8) and placebo group (10.9) at baseline were not significantly different (P=0.821). After adjustment for baseline Borg Cough Scale score and post-nasal drip, the mean between-group difference was not significant for LCQ-T total score (-1.26; 95% confidence interval [CI], -2.69 to 0.17), physical domain score (-0.35; 95% CI, -0.76 to 0.06), psychological domain score (-0.53; 95% CI, -1.06 to 0.01), or social domain score (-0.38; 95% CI, -0.92 to 0.16). Large improvements in LCQ-T total score were reported in both groups after 2 weeks (procaterol, 4.21±2.73; placebo, 5.34±3.2), and 4 weeks (procaterol, 5.94±3.68; placebo, 7.07±3.44). No differences between groups were found in the mean changes of spirometry or IOS parameters after 4 weeks.


Our study shows that procaterol is not effective in the treatment of PIC, in terms of improvement of cough-specific QoL or peripheral-airway function.


Cough that persists following an upper respiratory tract infection (URTI) in previously healthy subjects is termed “postinfectious cough” (PIC). PIC can be a disabling medical condition. Four underlying mechanisms of airway narrowing and hyperresponsiveness have been postulated [1-3]. First, epithelial necrosis may contribute to airway narrowing and damage to the ciliated epithelium, resulting in irreversible obstruction of peripheral airways [2]. Second, animal studies have shown that viral infection reduces the activity of neural endopeptidases from exposed sensory nerves and increases susceptibility to neurogenic inflammation by allowing a higher concentration of substance P to reach their receptors in the airways [4]. Third, in vitro studies have shown enhancement of immunoglobulin E-mediated histamine release from mononuclear leucocytes [5-7]. Also, release of inflammatory mediators, such as leukotriene C4, in nasopharyngeal secretions during acute viral infection has been reported in pediatric populations [8]. Finally, there is an increase in cough sensitivity to capsaicin that does not affect the caliber or responsiveness of airways [9]. A previous study proposed that various types of stimulations are not directly transmitted to cough receptors in the airways, but they can cause contraction of bronchial smooth muscle, which stimulates cough receptors to trigger cough [10].
Therapeutic trials of PIC with albuterol [11], nasal decongestants, antihistamines, inhaled corticosteroids [12,13], cough suppressants, and ipratropium bromide [14] have yielded unpredictable results. In this study, we hypothesized that procaterol may have an effect on the bronchial smooth muscle and possibly ameliorate cough mediated through an adrenergic pathway, and investigated the effects of procaterol on cough-specific quality of life (QoL) and peripheral-airway function using impulse oscillometry (IOS) among adults suffering from PIC.


1. Participants

The study protocol was approved by the Committee of the Ethics in Human Research of Ramathibodi Hospital (ID 07-57-26). All participants provided written informed consent before participation. This trial is registered with ClinicalTrials.gov (NCT 02349919).
Participants with PIC were defined as adults (age ≥18 years) having cough with a duration of 3–8 weeks following an acute URTI (sore/irritated throat, nasal congestion/discharge, or cough with or without fever). If the participants reported consecutive URTI within 8 weeks before resolution of the cough from the first URTI onset, the duration of cough was counted from the first URTI onset. The exclusion criteria were history of allergy or intolerance to β2 agonists; chronic diseases associated with cough (e.g., bronchiectasis, asthma, chronic obstructive pulmonary disease, and congestive heart failure); current or recent ex-smoker (<2 months); pregnancy; breastfeeding; treatment with drugs that can cause cough (e.g., angiotensin-converting enzyme inhibitors); wheezing or rhonchi on physical examination at screening; and abnormal chest radiographs.

2. Randomization and Masking

Participants were randomly assigned to receive procaterol (25-µg tablets) or identical placebo tablets (Otsuka Pharmaceuticals, Tokyo, Japan) with a 1:1 allocation. The randomization sequence was computer-generated by an independent statistician and was implemented using sequentially numbered packages. Participants, investigators, and research staff were masked to treatment allocation.

3. Procedures

On the screening visit at pulmonary clinic, research staff recorded the presence and onset of URTI symptoms (sneezing, blocked nose, or runny nose), duration of cough, post-nasal drip symptom, previous medications used for cough, history of allergic rhinitis, and smoking status of the participant. Each participant was evaluated to determine if he/she had symptoms suggestive of gastroesophageal reflux using the Gastroesophageal Reflux Disease Questionnaire (GERD-Q), and the severity of his/her cough symptom was rated on a 10-cm Borg Cough Scale (0, no cough; 10, maximum/excruciating cough).
All participants underwent physical examination of the nose, throat, and chest by our investigators who were pulmonologists. The findings (i.e., post-nasal drip, swollen or pale inferior turbinate, wheeze, or rhonchi) were recorded. Radiographs of the chest and paranasal sinuses were obtained in all participants. Participants with history of acute URTI and previous history of allergic rhinitis or sinusitis were allowed to participate in the study, if their cough persisted after they had been well-treated with nasal steroids and/or antibiotics for at least 2 weeks before randomization.
After clear instructions by our investigators, participants completed the Thai version of the Leicester Cough Questionnaire (LCQ-T). The total score of the LCQ-T can be from 3 to 21, with a higher score indicating a better cough-specific QoL [15]. The LCQ-T has been validated in a Thai population with chronic cough and the minimum clinically important difference has been determined [16,17]. Participants performed spirometry and methacholine challenge testing to determine whether they had baseline airway obstruction and to assess for airway hyperresponsiveness. We included those who had no airway obstruction, regardless of airway hyperresponsiveness, in the final analysis. Methacholine challenge testing was carried out in accordance with a standard guideline using a five-breath dosimeter protocol in which the test started from the diluent and proceeded with subsequent five incremental serial concentrations of methacholine solution (0.25, 1, 5, 10, 25 mg/mL) [18]. All solutions were delivered by a nebulizer (De Vilbiss 646; S&M Instruments, Doylestown, PA, USA). The final concentration of methacholine that decreased the baseline forced expiratory volume in one second (FEV1) by 20% (PC20) was recorded. Participants were excluded from the study if spirometry revealed an evidence of airway obstruction (i.e., FEV1/forced vital capacity <0.7), or if they had a GERD-Q score >8 [19]. Participants who had received medications previously for a URTI were asked to discontinue all medications before randomization and during the 4-week trial.
During the randomization visit, participants were asked to complete the LCQ-T and rate their severity of cough on the Borg Cough Scale, as well as complete the validated 36-item Short-Form Health Survey (SF-36) version 2.0 for general QoL [20]. IOS using Masterscreen IOS version 4.5 (Erish Jaeger, Hoechberg, Germany) with a standard method [21], spirometry, and fractional exhaled nitric oxide (FeNO) at exhaled flow of 50 mL/s (NObreath; Bedfont Scientific, Maidstone, UK), were measured. Our investigators then assigned participants to receive the study drug in a package containing 10 procaterol (25 µg) or identical placebo tablets twice daily. All participants were asked to avoid taking self-administered treatment for cough. After 2 weeks, participants were asked to follow-up at the clinic, and research staff counted the doses of tablets taken. Participants were given their study drug to continue for an additional 2 weeks if they did not report adverse effects or did not refuse to continue the study.
At 2 weeks and 4 weeks, participants were asked to complete the LCQ-T, Borg Cough Scale and SF-36. At each visit, IOS, spirometry, and FeNO measurements were obtained.
The primary outcome was the difference in LCQ-T total score between baseline and two follow-up points (2 weeks and 4 weeks). Secondary outcomes were the mean difference of the following parameters between baseline and 4 weeks: (1) spirometry parameters (FEV1, forced expiratory flow25%–75%), IOS parameters (resistance at 5 Hz [R5] and at 20 Hz [R20], difference of R5 and R20 [R5–R20], resonant frequency [Fres], reactance at 5 Hz [X5]), and FeNO levels; (2) SF-36 domain score.

4. Statistical Analyses

The sample size was calculated based on previous studies to have 80% power to detect the changes of the LCQ-T total score of 3, using a standard deviation (SD) of 4.0 and two-tailed α of 0.05 [15,17]. The ratio of intervention/control was set at 1:1. The target sample size was 60 participants. Allowing for a 20% dropout rate, the effective sample size was 74 participants.
The baseline characteristics of patients in treatment and placebo groups are described as the mean (SD) or median (range). To compare the baseline data between the two groups, an independent t-test or Mann-Whitney test for continuous variables and chi-square test for categorical variables were used. A mixed linear regression model was applied to assess the treatment effect on LCQ-T scores, SF-36, and pulmonary function parameters. Within-subject variation was fitted in the model as a random effect whereas the treatment was considered as a fixed effect. Time at measurement (i.e., 2 weeks and 4 weeks) was included in the mixed model by treating it as a fixed effect. Marginal effects on treatment, between treatment and time were compared. Covariables (baseline Borg Cough Scale score, post-nasal drip, and X5 value) were adjusted in the model. Intention-to-treat analyses were carried out for all outcomes. Per-protocol analyses were carried out for LCQ-T total and domain scores in participants who met the criteria for study eligibility, showed adherence to the study drug (defined as taking ≥50% of tablets), did not take self-administered medications for cough, and completed baseline and follow-up LCQ-T. Mixed-effects logistic regression analyses adjusted for these same baseline covariates were performed to assess between-group differences in improvement of LCQ-T total scores. All analyses were carried out by STATA ver. 15.0 (Stata Corp., College Station, TX, USA). A P-value <0.05 was considered significant.


Between July 1, 2015 and December 30, 2017, 100 participants were screened for trial eligibility. Of these, 74 were randomly allocated to receive procaterol (n=37) or placebo (n=37). Of the 74 participants, two met the PC20 at 0.29 mg/dL and 8.4 mg/dL of methacholine at the time of enrolment. Figure 1 summarizes the recruitment and follow-up of participants. The protocol violation of participants (i.e., refusing to take the study drug after enrolment but able to follow-up for taking the LCQ-T at 2 weeks and 4 weeks) during the trial did not differ between groups (one in each group). Table 1 summarizes the baseline characteristics, baseline LCQ-T total score and domain scores, baseline pulmonary function, and FeNO levels of participants. Participants receiving procaterol reported a significantly higher Borg Cough Scale score and worse post-nasal drip at baseline than those receiving placebo (P=0.031 and P=0.001, respectively). Participants receiving placebo showed a significant increase in markers of dysfunction of peripheral airways at baseline from IOS (higher Fres, greater reduction of X5) compared with those receiving procaterol (P=0.025 and P=0.011, respectively).
Table 2 summarizes the LCQ-T total and domain scores between procaterol and placebo groups. The adjusted mean between-group difference for LCQ-T total score and domain scores did not differ. The crude treatment effects of each group at 2 weeks and 4 weeks are summarized in Supplementary Table 1. Large improvements in LCQ-T total score were observed in both groups at 2 weeks (procaterol, 4.21±2.73; placebo, 5.34±3.2) and 4 weeks (procaterol, 5.94±3.68; placebo, 7.07±3.44). Between-group differences in LCQ-T total score and three domain scores after 2 weeks and 4 weeks were not significant, except for worsening psychological domains in the procaterol group in the per-protocol analysis (Supplementary Table 2). We assessed the interaction effect between treatment and time. There was no interaction effect between treatment and time (i.e., the mean differences of LCQ-T score between the procaterol group and the control group at 2 weeks and 4 weeks were not different). Therefore, we fit the mixed linear regression model without an interaction effect. The likelihood of a large improvement in LCQ-T total score >20% from baseline was similar in both groups (adjusted risk ratio, 0.78; 95% confidence interval [CI], 0.53–1.03). The adjusted mean between-group difference for pulmonary function parameters and FeNO levels is illustrated in Figure 2 and Supplementary Table 3. The mean between-group difference for SF-36 domain scores is shown in Supplementary Figure 1 and Supplementary Table 4.
Adverse events are summarized in Table 3. One of the four participants with palpitations in the procaterol group discontinued the study drug after the second day of enrolment. The remaining participants with palpitations completed the trial after reduction to half the drug dose. One of the two participants with dizziness in the placebo group discontinued the study drug, 2 weeks after enrolment. Other reported adverse events were not associated with withdrawal of the study drug. All participants who stopped the study drug prematurely owing to adverse events returned for outcome measurements at 2 weeks and 4 weeks.


Procaterol did not improve cough-specific QoL for patients with PIC. Large improvements in cough-specific QoL were reported in the procaterol and placebo groups, suggesting that PIC tends to improve spontaneously over time.
As reported in several studies, the mechanism of PIC includes cough-reflex hypersensitivity [9,22] and transient vocal dysfunction [23]. Other postulated mechanisms include the release of cytokines, neurotransmitters, and leukotrienes; increased levels of neural receptors (i.e., substance P); and modulation of afferent neural activity possibly via cholinergic motor pathways [24].
Ipratropium bromide was studied in patients with post-viral cough in a controlled double-blind trial [14]. The authors concluded that ipratropium bromide is effective for reducing cough without affecting bronchodilation in this condition. The observation should be interpreted cautiously given the small sample size, and the possibility of a carry-over effect of treatment owing to a crossover design, and no ‘true’ placebo. While procaterol is a smooth muscle relaxant, it can also reduce eosinophilic inflammation through the downregulation of the expression of adhesion molecules and inhibition of eosinophil migration in vitro [25]; inhibition of substance P release; and attenuation of histamine-induced cough during bronchoconstriction in animals [26].
We found no bronchoconstriction at baseline, and only two of the 74 participants (2.7%) showed methacholine-induced bronchoconstriction. These observations may explain the lack of effectiveness of procaterol on the number of coughs. FeNO was considered to be a marker of eosinophilic inflammation in our trial. We found a broad range of FeNo levels in PIC, and there was no significant change in FeNO levels at 2 weeks or 4 weeks in either group. Fujimura et al. [27] showed that inhaled procaterol had no effect on airway cough receptor sensitivity to capsaicin compared with placebo in patients without asthma and chronic bronchitis. That observation could at least in part explain why PIC does not respond to procaterol.
A greater percentage of participants had post-nasal drip and a higher Borg Cough Scale score at baseline in the procaterol group. There was a greater reduction in X5 in the placebo group. The main analysis was adjusted by these factors for the primary outcome and all secondary outcomes. Procaterol did not improve LCQ-T total score and domain scores compared with placebo. The results from our study are similar to the results from a systematic review of inhaled β2 agonists in children with nonspecific chronic cough, in terms of the lack of reduction of cough frequency [28]. In a study by Holmes et al. [14], an inhaled bronchodilator had no effect compared with placebo in the improvement of spirometry. We thought that the measurement of airway resistance by IOS, which is reportedly more sensitive to detect abnormalities compared to spirometry, contributed to the difference of our study from previous reports. In our study, the bronchodilator had no effect compared with placebo with respect to spirometry, IOS parameters, and FeNo levels. Large improvements in cough-specific QoL were observed in procaterol and placebo groups after 2 weeks and 4 weeks, suggestive of natural resolution of PIC.
We acknowledge potential limitations. First, the sample size was relatively small. This was because the sample size was calculated based on a larger change of total LCQ score (i.e., 3) from previous studies [15,17]. However, the threshold of changes in the total LCQ score could be achieved. A back-calculation of the power of our trial was 70%, but the lower boundary of the 95% CI of the treatment effect nearly reached 3 (i.e., 2.69), which was unfavourable towards the procaterol group. The sample size was recalculated for regression analysis, and 60 participants in each group are suggested for future trials. Second, the duration of cough in four patients was longer than those commonly defined for PIC. There are several explanations. First, the duration of cough in this study was counted from the first URTI onset in patients with recurrent episodes of URTI (n=2), therefore cough duration could be >8 weeks up to 13 weeks. Secondly, the cough duration was protracted because of proven influenza (n=2). As previously reported, cough due to pertussis and H1N1 influenza infections, may be prolonged (median: 118 days and 3 months, respectively), as compared with that due mycoplasma or other respiratory viral infections [29,30]. Yet, the tests for both organisms were not obtained. Third, we did not carry out microbiologic investigations of other possible organisms causing PIC, such as Mycoplasma, Chlamydia, or Bordetella pertussis. However, the inclusion criteria for participation in the trial were quite robust, in that a clinical definition of PIC was combined with other investigations before study entry (e.g., radiographs of the chest and paranasal sinuses, spirometry) to exclude significant underlying diseases that can exacerbate cough during URTI. Fourth, although several parameters (i.e., airway responsiveness and inflammation) were measured, the cough-reflex sensitivity was not tested to elucidate the mechanism of cough in our trial. Finally, our trial was conducted at the tertiarycare level where thorough investigations of chronic cough were fulfilled. However, our findings might not be generalizable to the primary-care setting.
In conclusion, in our study, we found that oral procaterol did not ameliorate cough that persisted following URTI. Spirometry parameters, peripheral-airway function, and exhaled nitric oxide level did not improve with procaterol administration, suggesting that PIC does not relate to airway obstruction and tends to improve spontaneously over time.


No potential conflict of interest relevant to this article was reported.


This was an investigator initiated trial funded by Otsuka Pharmaceuticals (Thailand). The company was not involved in the study design; collection, analyses or interpretation of data; report writing; or submission for publication. The primary investigator constructed the study protocol and bore final responsibility for the decision to submit this manuscript for publication. We thank Arshad Makhdum, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.


Supplementary materials can be found via https://doi.org/10.4082/kjfm.19.0118.
Supplementary Table 1.
Descriptive information of the LCQ-T between procaterol and placebo groups (intention-to-treat-analysis)
Supplementary Table 2.
Descriptive information of the LCQ-T score after 4 weeks between procaterol and placebo groups (per-protocol analyses)
Supplementary Table 3.
Descriptive information of spirometry parameters, impulse oscillometry parameters, and FeNO levels after 4 weeks between procaterol and placebo groups
Supplementary Table 4.
Descriptive information of SF-36 domain score after 4 weeks between procaterol and placebo groups
Supplementary Figure 1.
Mean difference of SF-36 domain score between procaterol and placebo groups.

Figure. 1.
Flow diagram of the study. LCQ, Leicester Cough Questionnaire.
Figure. 2.
Plot showing the mean difference (95% CI) of pulmonary function parameters and FeNO levels. Values are the mean difference derived from the regression model (placebo as a reference). Adjustment for baseline Borg Cough Scale score, baseline post-nasal drip, and baseline X5 value was analyzed. CI, confidence interval; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; FEF25%–75%, forced expiratory flow between 25% and 75% of FVC; R5, respiratory resistance at 5 Hz; R20, respiratory resistance at 20 Hz; R5−R20, difference between R5 and R20; Fres, resonant frequency; X5, reactance at 5 Hz; AX, reactance area; FeNO, fractional exhaled nitric oxide.
Table 1.
Baseline characteristics of subjects administered procaterol or placebo
Characteristic Procaterol (n=37) Placebo (n=37) P-value
Sex 0.465
 Female 22 (59.5) 26 (70.3)
 Male 15 (40.5) 11 (29.7)
Age (y) 39.4±14.2 41.8±12.5 0.437
Duration of previous URTI (wk) 4 (2–13) 4 (2–12) 1.000
Duration of cough (wk) 4 (3–12) 3 (3–13) 0.805
Post-nasal drip 25 (67.6) 11 (29.7) 0.001
Nasal symptoms 32 (86.5) 26 (70.3) 0.090
Ex-smoker 3 (8.1) 4 (10.8) 1.000
Non-smoker 34 (91.9) 33 (89.2)
Allergic rhinitis 17 (45.9) 12 (32.4) 0.234
History of prior treatments
 Inhaled B2 agonists 3 (8.11) 1 (2.7) 0.448
 Antibiotics 20 (54.0) 18 (48.6) 0.607
 Corticosteroids 7 (18.9) 7 (18.9) 0.422
 Cough suppressants 12 (32.4) 12 (32.4) 0.730
 Nasal decongestants 8 (21.6) 6 (16.2) 0.191
 Antihistamines 14 (37.8) 16 (43.2) 0.224
GERD-Q 5.8±2.8 6.1±1.6 0.573
Borg Cough Scale score 5.0±1.8 4.1±2.0 0.031
LCQ-T score
 Total score 10.76±2.3 10.92±3.6 0.821
 Physical domain 3.99±0.9 3.94±1.0 0.812
 Psychological domain 3.44±0.8 3.59±1.4 0.556
 Social domain 3.34±0.9 3.39±1.5 0.852
 Physical 75.0±21.1 78.2±21.2 0.511
 Role physical 74.5±23.9 74.7±28.5 0.978
 Body pain 70.5±22.5 71.6±23.8 0.841
 General health 54.7±21.1 58.2±21.1 0.473
 Vitality 59.1±17.6 63.7±18.3 0.279
 Social function 69.6±22.1 73.3±23.0 0.482
 Role emotion 74.8±20.9 78.8±24.2 0.443
 Mental health 65.5±18.1 72.6±19.3 0.110
 FVC (% predicted) 94.4±12.7 92.2±13.3 0.466
 FEV1 (% predicted) 91.3±10.8 87.5±11.4 0.142
 FEV1/FVC (%) 83.0±6.2 82.0±5.9 0.479
 FEF25%–75% (% predicted) 89.9±23.2 83.5±21.8 0.228
Impulse oscillometry
 R5 (cmH2O/L/s) 3.58±1.03 3.92±1.20 0.193
 R20 (cmH2O/L/s) 2.78±0.75 3.01±0.91 0.245
 R5−R20 (cmH2O/L/s) 0.71 (0.12–3.04) 0.86 (0.08–2.32) 0.315
 Fres (Hz) 13.31±3.01 15.03±3.40 0.025
 X5 (cmH2O/L/s) -1.36±0.41 -1.62±0.58 0.011
 FeNo (ppb) 14.5 (2–57) 14.5 (1–175) 1.000

Values are presented as number (%), mean±standard deviation, or median (range).

URTI, upper respiratory tract infection; GERD-Q, Gastroesophageal Reflux Disease Questionnaire; LCQ-T, Thai version of the Leicester Cough Questionnaire; SF-36, 36-item Short-Form Health Survey; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; FEF25%–75%, forced expiratory flow between 25% and 75% of FVC; R5, respiratory resistance at 5 Hz; R20, respiratory resistance at 20 Hz; R5−R20, difference between R5 and R20; Fres, resonant frequency; X5, reactance at 5 Hz; FeNO, fractional exhaled nitric oxide.

Table 2.
Comparison of the LCQ-T score after 4 weeks between procaterol and placebo groups (intention-to-treat analyses)
Intervention LCQ-T
Total Physical Psychological Social
 Procaterol -1.26 (-2.69 to 0.17) -0.35 (-0.76 to 0.06) -0.53 (-1.06 to 0.01) -0.38 (-0.92 to 0.16)
 Placebo 0 0 0 0
Borg Cough Scale score at baseline -0.59 (-0.94 to -0.24) -0.18 (-0.28 to -0.09) -0.17 (-0.30 to -0.04) -0.23 (-0.36 to 0.10)
Post-nasal drip 0.78 (-0.62 to 2.18) 0.17 (-0.23 to 0.57) 0.35 (-0.18 to 0.87) 0.26 (-0.27 to 0.79)
X5 at baseline 0.82 (-0.52 to 2.16) 0.35 (-0.03 to 0.73) 0.19 (-0.31 to 0.69) 0.27 (-0.23 to 0.78)

Values are presented as mean difference LCQ-T scores (95% confidence interval), adjusted for baseline Borg Cough Scale score, baseline post-nasal drip, and baseline X5 value. By intention-to-treat analyses.

LCQ-T, Thai version of the Leicester Cough Questionnaire; X5, reactance at 5 Hz.

Table 3.
Adverse events
Adverse event Procaterol Placebo
Palpitation 4 1
Dizziness 2 0
Hand tremor 2 0
Tachycardia 1 0

Values are presented as total number of events.


1. Hegele RG, Hayashi S, Hogg JC, Pare PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995;151:1659–64.
crossref pmid
2. Blair HT, Greenberg SB, Stevens PM, Bilunos PA, Couch RB. Effects of rhinovirus infection of pulmonary function of healthy human volunteers. Am Rev Respir Dis 1976;114:95–102.
3. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976;113:131–9.
4. Borson DB, Brokaw JJ, Sekizawa K, McDonald DM, Nadel JA. Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections. J Appl Physiol (1985) 1989;66:2653–8.
crossref pmid
5. Busse WW, Swenson CA, Borden EC, Treuhaft MW, Dick EC. Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol 1983;71:382–8.
crossref pmid
6. Chonmaitree T, Lett-Brown MA, Grant JA. Respiratory viruses induce production of histamine-releasing factor by mononuclear leukocytes: a possible role in the mechanism of virus-induced asthma. J Infect Dis 1991;164:592–4.
crossref pmid pdf
7. Ida S, Hooks JJ, Siraganian RP, Notkins AL. Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon. J Exp Med 1977;145:892–906.
crossref pmid pmc pdf
8. Volovitz B, Faden H, Ogra PL. Release of leukotriene C4 in respiratory tract during acute viral infection. J Pediatr 1988;112:218–22.
crossref pmid
9. O’Connell F, Thomas VE, Studham JM, Pride NB, Fuller RW. Capsaicin cough sensitivity increases during upper respiratory infection. Respir Med 1996;90:279–86.
crossref pmid
10. Salem H, Aviado DM. Antitussive drugs, with special reference to a new theory for the initation of the cough reflex and the influence or bronchodilators. Am J Med Sci 1964;247:585–600.
crossref pmid
11. Hueston WJ. A comparison of albuterol and erythromycin for the treatment of acute bronchitis. J Fam Pract 1991;33:476–80.
12. Frank A, Dash CH. Inhaled beclomethasone dipropionate in acute infections of the respiratory tract. Respiration 1985;48:122–6.
crossref pmid
13. Pornsuriyasak P, Charoenpan P, Vongvivat K, Thakkinstian A. Inhaled corticosteroid for persistent cough following upper respiratory tract infection. Respirology 2005;10:520–4.
crossref pmid
14. Holmes PW, Barter CE, Pierce RJ. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 1992;86:425–9.
crossref pmid
15. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003;58:339–43.
crossref pmid pmc
16. Pornsuriyasak P, Kawamatawong T, Rattanasiri S, Tantrakul V, Pongmesa T, Birring SS, et al. Validity and reliability of the Thai version of the leicester cough questionnaire in chronic cough. Asian Pac J Allergy Immunol 2016;34:212–6.
17. Pornsuriyasak P, Thungtitigul P, Kawamatawong T, Birring SS, Pongmesa T. Minimal clinically important differences (MCIDs) of the thai version of the leicester cough questionnaire for subacute and chronic cough. Value Health Reg Issues 2017;12:57–62.
crossref pmid
18. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309–29.
crossref pmid
19. Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J 2013;1:175–83.
crossref pmid pmc
20. Jirarattanaphochai K, Jung S, Sumananont C, Saengnipanthkul S. Reliability of the medical outcomes study short-form survey version 2.0 (Thai version) for the evaluation of low back pain patients. J Med Assoc Thai 2005;88:1355–61.
21. Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003;22:1026–41.
crossref pmid
22. Dicpinigaitis PV, Bhat R, Rhoton WA, Tibb AS, Negassa A. Effect of viral upper respiratory tract infection on the urge-to-cough sensation. Respir Med 2011;105:615–8.
crossref pmid
23. Taramarcaz P, Grissell TV, Borgas T, Gibson PG. Transient postviral vocal cord dysfunction. J Allergy Clin Immunol 2004;114:1471–2.
crossref pmid
24. Dicpinigaitis PV. Effect of viral upper respiratory tract infection on cough reflex sensitivity. J Thorac Dis 2014;6:S708–11.
pmid pmc
25. Tashimo H, Yamashita N, Ishida H, Nagase H, Adachi T, Nakano J, et al. Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol Int 2007;56:241–7.
crossref pmid
26. Sekizawa K, Ebihara T, Sasaki H. Role of substance P in cough during bronchoconstriction in awake guinea pigs. Am J Respir Crit Care Med 1995;151:815–21.
crossref pmid
27. Fujimura M, Sakamoto S, Kamio Y, Bando T, Kurashima K, Matsuda T. Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. Thorax 1993;48:615–8.
crossref pmid pmc
28. Tomerak AA, Vyas H, Lakenpaul M, McGlashan JJ, McKean M. Inhaled beta2-agonists for treating non-specific chronic cough in children. Cochrane Database Syst Rev 2005;CD005373.
29. Wang K, Chalker V, Bermingham A, Harrison T, Mant D, Harnden A. Mycoplasma pneumoniae and respiratory virus infections in children with persistent cough in England: a retrospective analysis. Pediatr Infect Dis J 2011;30:1047–51.
crossref pmid
30. Ryan NM, Vertigan AE, Ferguson J, Wark P, Gibson PG. Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection. Respir Med 2012;106:138–44.
crossref pmid


Browse all articles >

Editorial Office
Room 2003, Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
Tel: +82-2-3210-1537    Tax: +82-2-3210-1538    E-mail: kjfm@kafm.or.kr                

Copyright © 2021 by Korean Academy of Family Medicine.

Developed in M2PI

Close layer
prev next